Intratumoral heterogeneity of HER2 status in breast carcinoma;Intratumorale HER2-Heterogenität des invasiven Mammakarzinoms

Pathologe

Volumn 31, Issue SUPPL. 2, 2010, Pages 292-295

  Ohlschlegel C ^a   Zahel, K ^a   Kradolfer, D ^a   Hell, M ^a   Jochum, W ^a  

^a Institut für Pathologie Kantonsspital St Gallen   (Switzerland)

Author keywords

Breast carcinoma; Genetic heterogeneity; HER2

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HER2 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BREAST TUMOR; CANCER INVASION; CHROMOSOME 17; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENETIC HETEROGENEITY; GENETICS; HUMAN; METHODOLOGY; PATHOLOGY; PRACTICE GUIDELINE; PROGNOSIS;

BREAST NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC HETEROGENEITY; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; NEOPLASM INVASIVENESS; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 79953186161     PISSN: 01728113     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00292-010-1316-z     Document Type: Article

References (19)

1. Andersson J, Linderholm B, Bergh J et al (2004) HER-2/neu (c-erbB-2) evaluation in primary breast carcinoma by fluorescent in situ hybridization and immunohistochemistry with special focus on intratumor heterogeneity and comparison of invasive and in situ components. Appl Immunohistochem Mol Morphol 12:14-20
2. Brunelli M, Manfrin E, Martignoni G et al (2009) Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria. Am J Clin Pathol 131:678-682
3. Gancberg D, Di Leo A, Cardoso F et al (2002) Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 13:1036-1043
4. Glockner S, Buurman H, Kleeberger W et al (2002) Marked intratumoral heterogeneity of c-myc and cyclinD1 but not of c-erbB2 amplification in breast cancer. Lab Invest 82:1419-1426
5. Hanna W, Nofech-Mozes S, Kahn HJ (2007) Intratumoral heterogeneity of HER2/neu in breast cancer-a rare event. Breast J 13:122-129
6. Lewis JT, Ketterling RP, Halling KC et al (2005) Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining. Am J Clin Pathol 124:273-281
7. MA Y, Lespagnard L, Durbecq V et al (2005) Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice. Clin Cancer Res 11:4393-4399
8. Nassar A, Radhakrishnan A, Cabrero IA et al (2010) Intratumoral heterogeneity of immunohistochemical marker expression in breast carcinoma: a tissue microarray-based study. Appl Immunohistochem Mol Morphol [Epub ahead of print May 18]
9. Pertschuk LP, Axiotis CA, Feldman JG et al (1999) Marked intratumoral heterogeneity of the proto-oncogene Her-2/neu determined by three different detection systems. Breast J 5:369-374
10. Regitnig P, Schippinger W, Lindbauer M et al (2004) Change of HER-2/neu status in a subset of distant metastases from breast carcinomas. J Pathol 203:918-926
11. Rüschoff J, Nagelmeier I, Hofmann M et al (2009) ErbB2 diagnostics in breast cancer-an update. Pathologe 30:147-155
12. Sauter G, Lee J, Bartlett JM et al (2009) Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 27:1323-1333
13. Shin SJ, Hyjek E, Early E et al (2006) Intratumoral heterogeneity of her-2/neu in invasive mammary carcinomas using fluorescence in-situ hybridization and tissue microarray. Int J Surg Pathol 14:279-284
14. Szollosi J, Balazs M, Feuerstein BG et al (1995) ERBB-2 (HER2/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer. Cancer Res 55:5400-5407
15. Tapia C, Savic S, Wagner U et al (2007) HER2 gene status in primary breast cancers and matched distant metastases. Breast Cancer Res 9:R31
16. Tubbs RR, Hicks DG, Cook J et al (2007) Fluores-cence in situ hybridization (FISH) as primary methodology for the assessment of HER2 Status in adenocarcinoma of the breast: a single institution experience. Diagn Mol Pathol 16:207-210
17. Vance GH, Barry TS, Bloom KJ et al (2009) Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch Pathol Lab Med 133:611-612
18. Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145
19. Wu JM, Halushka MK, Argani P (2010) Intratumoral heterogeneity of HER-2 gene amplification and protein overexpression in breast cancer. Hum Pathol 41:914-917